Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Massimo Loda, M.D.

Co-Author

This page shows the publications co-authored by Massimo Loda and Carmen Priolo.
Connection Strength

3.835
  1. Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. Mol Cell Oncol. 2015 Oct-Dec; 2(4):e1001197.
    View in: PubMed
    Score: 0.605
  2. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014 Dec 15; 74(24):7198-204.
    View in: PubMed
    Score: 0.594
  3. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol. 2010 Apr; 176(4):1901-13.
    View in: PubMed
    Score: 0.430
  4. Unraveling the metabolome in prostate tumorigenesis: Effects by an oncogenic isopeptidase. J Clin Oncol. 2009 May 20; 27(15_suppl):e16148.
    View in: PubMed
    Score: 0.408
  5. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs. 2009 Mar; 12(3):165-8.
    View in: PubMed
    Score: 0.402
  6. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006 Sep 01; 66(17):8625-32.
    View in: PubMed
    Score: 0.338
  7. USP2a is an oncogenic isopeptidase and a potential target in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14522.
    View in: PubMed
    Score: 0.333
  8. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014; 6(10):1357.
    View in: PubMed
    Score: 0.147
  9. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 04; 6(4):519-38.
    View in: PubMed
    Score: 0.141
  10. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res. 2010 Jul 01; 16(13):3322-8.
    View in: PubMed
    Score: 0.109
  11. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
    View in: PubMed
    Score: 0.101
  12. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
    View in: PubMed
    Score: 0.098
  13. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
    View in: PubMed
    Score: 0.037
  14. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3680-9.
    View in: PubMed
    Score: 0.026
  15. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009 May; 119(5):1093-108.
    View in: PubMed
    Score: 0.025
  16. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab. 2006 Jun; 91(6):2021-6.
    View in: PubMed
    Score: 0.021
  17. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res. 2006 Feb; 4(2):79-92.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.